dcc-3116
deciphera
['agent', 'dcc-3116', 'deciphera']
we re proud to present initial data from the single agent dose escalation portion of the phase 1 study of our investigational first-in-class ulk inhibitor, dcc-3116, at #esmo2022. learn more about this exciting new data: 
Deciphera is a biopharmaceutical company focused on discovering, developing & commercializing important new medicines to improve the lives of people with cancer